Feasibility of “Symptom Discovery,” a Longitudinal and Comprehensive Data Collection Tool During COVID-19.

Publication date: Jan 25, 2024

There are few patient- or public-facing tools for longitudinal and comprehensive symptom assessment, especially when faced with an uncharacterized condition such as COVID-19 or a chronic condition in which symptoms have not been adequately specified. To address this need, we developed the Symptom Discovery mobile application and tested its feasibility with the US public early in the COVID-19 pandemic. Although there were challenges, results showed feasibility and acceptance.

Open Access PDF

Concepts Keywords
Covid COVID-19
Discovery COVID-19 pandemic
Pandemic Data Collection
Patient feasibility assessment
Feasibility Studies
Mobile Applications
mobile health
Symptom tracking


Type Source Name
disease IDO symptom
disease MESH COVID-19
disease MESH chronic condition
disease VO USA
disease VO report
disease MESH infection
disease VO time
disease VO Gap
disease IDO history
disease IDO blood
drug DRUGBANK Oxygen
disease MESH influenza
disease VO biological sex
disease VO document
disease VO mouth
disease MESH syndrome
disease MESH long COVID
disease VO Hormone
disease MESH Infectious diseases
disease MESH Obesity
disease VO population
disease IDO infectious agent
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Bismuth subgallate

Original Article

(Visited 1 times, 1 visits today)